Key Points
- Insider Matthew Wiley sold 3,097 shares of Definium Therapeutics at an average price of $36.57, worth approximately $113,257. He retained 359,036 shares, and the transaction was conducted under a pre-arranged Rule 10b5-1 plan.
- Definium reported quarterly EPS of negative $1.44, missing the consensus estimate of negative $0.55. Analysts nevertheless maintain a generally positive outlook, with an average “Buy” rating and a consensus price target of $64.88.
- The stock opened at $38.21, with a market capitalization of approximately $5.13 billion and a 52-week range of $10.46 to $49.70. Institutional investors own about 27.91% of the company.
-inc-logo-1200x675.jpg?v=20240515130629)
Definium Therapeutics, Inc. (NASDAQ:DFTX - Get Free Report) insider Matthew Wiley sold 3,097 shares of the stock in a transaction on Friday, September 25th. The stock was sold at an average price of $36.57, for a total value of $113,257.29. Following the sale, the insider owned 359,036 shares in the company, valued at approximately $13,129,946.52. This represents a 0.86% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Definium Therapeutics Price Performance
Definium Therapeutics stock opened at $38.21 on Wednesday. The firm has a market capitalization of $5.13 billion, a P/E ratio of -11.14 and a beta of 2.23. Definium Therapeutics, Inc. has a one year low of $10.46 and a one year high of $49.70. The company has a debt-to-equity ratio of 0.04, a current ratio of 6.95 and a quick ratio of 6.95. The business has a fifty day moving average price of $41.37 and a 200-day moving average price of $32.06.
Definium Therapeutics (NASDAQ:DFTX - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported ($1.44) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.55) by ($0.89). As a group, equities research analysts forecast that Definium Therapeutics, Inc. will post -3.02 EPS for the current year.
Analyst Upgrades and Downgrades
A number of equities research analysts have recently issued reports on the stock. JonesTrading increased their price target on shares of Definium Therapeutics from $74.00 to $90.00 and gave the stock a "buy" rating in a report on Thursday, August 13th. UBS Group reaffirmed a "buy" rating and set a $70.00 price objective on shares of Definium Therapeutics in a research note on Tuesday, September 15th. Oppenheimer reaffirmed an "outperform" rating and set a $75.00 target price on shares of Definium Therapeutics in a report on Monday, September 14th. HC Wainwright reiterated a "buy" rating and issued a $70.00 target price on shares of Definium Therapeutics in a research note on Monday, September 14th. Finally, Leerink Partners set a $52.00 price target on shares of Definium Therapeutics and gave the company an "outperform" rating in a report on Monday, June 22nd. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $64.88.
Check Out Our Latest Stock Report on Definium Therapeutics
More Definium Therapeutics News
Here are the key news stories impacting Definium Therapeutics this week:
- Positive Sentiment: Definium granted stock options covering 334,810 shares to 15 newly hired non-executive employees. The hiring supports the company’s efforts to advance its pipeline of psychiatric and neurological therapies and expand its workforce. Definium Therapeutics Announces New Employee Inducement Grants
- Neutral Sentiment: The employee options may help attract and retain talent, but they also represent potential share dilution. The grants were inducement awards for new employees rather than a change to the company’s operating outlook.
- Negative Sentiment: Four insiders collectively sold 52,075 shares for approximately $1.90 million at an average price of $36.57. The sales included CEO Robert Barrow’s 31,550 shares, insider Mark Sullivan’s 14,051 shares, CFO Brandi Roberts’ 3,377 shares and Matthew Wiley’s 3,097 shares. Such concentrated selling can pressure sentiment and raise concerns about insider confidence, even though each seller retained a substantial position.
- Negative Sentiment: All four transactions were executed under pre-arranged Rule 10b5-1 trading plans, which reduces their significance as discretionary bearish signals but does not eliminate the near-term perception of increased insider selling.
Institutional Trading of Definium Therapeutics
Several institutional investors and hedge funds have recently modified their holdings of the business. Avoro Capital Advisors LLC bought a new stake in shares of Definium Therapeutics during the 4th quarter valued at about $66,950,000. Wellington Management Group LLP purchased a new position in shares of Definium Therapeutics during the second quarter worth about $138,755,000. Seven Fleet Capital Management LP bought a new position in shares of Definium Therapeutics in the second quarter worth approximately $6,992,000. Platinum Investment Management Ltd. bought a new position in shares of Definium Therapeutics in the fourth quarter worth approximately $937,000. Finally, TD Waterhouse Canada Inc. purchased a new stake in Definium Therapeutics in the second quarter valued at approximately $1,592,000. Hedge funds and other institutional investors own 27.91% of the company's stock.
About Definium Therapeutics
(
Get Free Report)
Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
